TP53 and Alzheimer disease: To determine whether the non‐genomic activation of VDR/p53 played a role in AD, we used a chemical inhibitor of p53 to block the negative activity of VDR/p53 and reverse the brain pathology and cognition impairment in the AD mouse model.